PMID- 32456359
OWN - NLM
STAT- MEDLINE
DCOM- 20210216
LR  - 20210216
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 10
DP  - 2020 May 24
TI  - The Role of Selected Chemokines and Their Receptors in the Development of 
      Gliomas.
LID - 10.3390/ijms21103704 [doi]
LID - 3704
AB  - Among heterogeneous primary tumors of the central nervous system (CNS), gliomas 
      are the most frequent type, with glioblastoma multiforme (GBM) characterized with 
      the worst prognosis. In their development, certain chemokine/receptor axes play 
      important roles and promote proliferation, survival, metastasis, and 
      neoangiogenesis. However, little is known about the significance of atypical 
      receptors for chemokines (ACKRs) in these tumors. The objective of the study was 
      to present the role of chemokines and their conventional and atypical receptors 
      in CNS tumors. Therefore, we performed a thorough search for literature 
      concerning our investigation via the PubMed database. We describe biological 
      functions of chemokines/chemokine receptors from various groups and their 
      significance in carcinogenesis, cancer-related inflammation, neo-angiogenesis, 
      tumor growth, and metastasis. Furthermore, we discuss the role of chemokines in 
      glioma development, with particular regard to their function in the transition 
      from low-grade to high-grade tumors and angiogenic switch. We also depict various 
      chemokine/receptor axes, such as CXCL8-CXCR1/2, CXCL12-CXCR4, CXCL16-CXCR6, 
      CX3CL1-CX3CR1, CCL2-CCR2, and CCL5-CCR5 of special importance in gliomas, as well 
      as atypical chemokine receptors ACKR1-4, CCRL2, and PITPMN3. Additionally, the 
      diagnostic significance and usefulness of the measurement of some chemokines and 
      their receptors in the blood and cerebrospinal fluid (CSF) of glioma patients is 
      also presented.
FAU - Groblewska, Magdalena
AU  - Groblewska M
AD  - Department of Biochemical Diagnostics, University Hospital in Bialystok, 15-269 
      Bialystok, Poland.
FAU - Litman-Zawadzka, Ala
AU  - Litman-Zawadzka A
AD  - Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 
      15-269 Bialystok, Poland.
FAU - Mroczko, Barbara
AU  - Mroczko B
AUID- ORCID: 0000-0002-4075-8479
AD  - Department of Biochemical Diagnostics, University Hospital in Bialystok, 15-269 
      Bialystok, Poland.
AD  - Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 
      15-269 Bialystok, Poland.
LA  - eng
GR  - SUB/1/DN/20/003/1198/Medical University of Bialystok, Poland/
PT  - Journal Article
PT  - Review
DEP - 20200524
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Chemokines)
RN  - 0 (Receptors, Chemokine)
SB  - IM
MH  - Animals
MH  - Chemokines/*metabolism
MH  - Glioma/etiology/*metabolism/physiopathology
MH  - Humans
MH  - Receptors, Chemokine/*metabolism
PMC - PMC7279280
OTO - NOTNLM
OT  - angiogenesis
OT  - atypical chemokine receptor
OT  - central nervous system tumor
OT  - chemokine
OT  - conventional chemokine receptor
OT  - glioma
OT  - inflammation
OT  - leukocyte
COIS- The authors declare no conflict of interest.
EDAT- 2020/05/28 06:00
MHDA- 2021/02/17 06:00
PMCR- 2020/05/01
CRDT- 2020/05/28 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/05/21 00:00 [revised]
PHST- 2020/05/22 00:00 [accepted]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/17 06:00 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - ijms21103704 [pii]
AID - ijms-21-03704 [pii]
AID - 10.3390/ijms21103704 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 May 24;21(10):3704. doi: 10.3390/ijms21103704.